Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus

被引：0
作者：
Anca D. Askanase
George J. Wan
Mary P. Panaccio
Enxu Zhao
Julie Zhu
Roman Bilyk
Richard A. Furie
机构：
[1] Columbia University Irving Medical Center,
[2] Mallinckrodt Pharmaceuticals,undefined
[3] Zucker School of Medicine at Hofstra/Northwell,undefined
来源：
Rheumatology and Therapy | 2021年 / 8卷
关键词：
Acthar Gel; Autoimmune disease; Glucocorticoid; Patient-reported outcomes; Repository corticotropin injection; Systemic lupus erythematosus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：573 / 584
页数：11
相关论文
共 50 条
  • [21] Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus
    Kayode J. Bello
    Hong Fang
    Parastoo Fazeli
    Waleed Bolad
    Mary Corretti
    Laurence S. Magder
    Michelle Petri
    Rheumatology International, 2013, 33 : 2789 - 2796
  • [22] Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus
    Bello, Kayode J.
    Fang, Hong
    Fazeli, Parastoo
    Bolad, Waleed
    Corretti, Mary
    Magder, Laurence S.
    Petri, Michelle
    RHEUMATOLOGY INTERNATIONAL, 2013, 33 (11) : 2789 - 2796
  • [23] Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial
    Zimmer, Robert
    Scherbarth, Hugo R.
    Luis Rillo, Oscar
    Jesus Gomez-Reino, Juan
    Muller, Sylviane
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (11) : 1830 - 1835
  • [24] A Randomized, Double-blind, Placebo-controlled Clinical Trial Examining the Effects of Green Tea Extract on Systemic Lupus Erythematosus Disease Activity and Quality of Life
    Shamekhi, Z.
    Amani, R.
    Habibagahi, Z.
    Namjoyan, F.
    Ghadiri, Ata
    Malehi, A. Saki
    PHYTOTHERAPY RESEARCH, 2017, 31 (07) : 1063 - 1071
  • [25] Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
    Stohl, William
    Schwarting, Andreas
    Okada, Masato
    Scheinberg, Morton
    Doria, Andrea
    Hammer, Anne E.
    Kleoudis, Christi
    Groark, James
    Bass, Damon
    Fox, Norma Lynn
    Roth, David
    Gordon, David
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (05) : 1016 - 1027
  • [26] Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
    Furie, Richard A.
    Bruce, Ian N.
    Doerner, Thomas
    Leon, Manuel Gustavo
    Leszczynski, Piotr
    Urowitz, Murray
    Haier, Birgit
    Jimenez, Teri
    Brittain, Claire
    Liu, Jiajun
    Barbey, Catherine
    Stach, Christian
    RHEUMATOLOGY, 2021, 60 (11) : 5397 - 5407
  • [27] Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
    Wallace, Daniel J.
    Kalunian, Kenneth
    Petri, Michelle A.
    Strand, Vibeke
    Houssiau, Frederic A.
    Pike, Marilyn
    Kilgallen, Brian
    Bongardt, Sabine
    Barry, Anna
    Kelley, Lexy
    Gordon, Caroline
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 183 - 190
  • [28] Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial
    Richardson, Paul G.
    Schlossman, Robert L.
    Roy, Anuja N.
    Panneerselvam, Ashok
    Acharyya, Suddhasatta
    Sopala, Monika
    Lonial, Sagar
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (05) : 628 - 636
  • [29] Methyl-donor supplementation in women with systemic lupus erythematosus with different nutritional status: the protocol for a randomised, double-blind, placebo-controlled trial
    da Mota, Jhulia C. N. L.
    Carvalho, Lucas M.
    Ribeiro, Amanda A.
    Souza, Leticia L.
    Borba, Eduardo F.
    Roschel, Hamilton
    Gualano, Bruno
    Nicoletti, Carolina F.
    LUPUS SCIENCE & MEDICINE, 2024, 11 (02):
  • [30] Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
    Merrill, Joan T.
    Shanahan, William R.
    Scheinberg, Morton
    Kalunian, Kenneth C.
    Wofsy, David
    Martin, Renee S.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (06) : 883 - 889
12345